Replies to post #130896 on NorthWest Biotherapeutics Inc (NWBO)

[Basin Street Blues]

Mouthwatering prospect...

There is no doubt Gilead need to hedge their Hep C future flows as they will significantly taper beyond 2022. Remember they paid $11bn for Pharmasset and that ended up being a great trade for them.

Also JNJ have $41bn in cash ....

In fact all large pharma could finance $10bn in a heart beat ..

[Etienne1]

Your evaluation for a buyout is so low that it's impressive! Have you considered nwbio's platform and it's potential to become the new standard of care, to treat solid tumors in different cancers, operable and inoperable?

Past buyouts for companies with nothing comparable to nwbio's have been in the range of 5-15 billions. Some posters have given exemples here.

So mine is 10x that, even though nwbio is low on cash, 60b would be right imo.

[monentum2play]

I had thought they are waiting for AA or Breakthrough therapy but they want to now get the minor endpoints finished. That tells me there would be no doubt or question on DCVAX if all endpoints met.